Bibliografía del artículo
1. Teefey SA, Hildeboldt CC, Dehdashti F et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology (2003) 226:533-542.
2. Helmberger T, Semelka RC. New contrast agents for imaging of the liver. Magn Reson Imaging Clin N Am (2003) 9:745-66.
3. Helmberger TK. Contrast agents for body MRI. Syllabus 13th scientific meeting Int´l society for magnetic resonance in medicine (2005), Mira Digital Publishing.
4. Gellissen J, Axmann C, Prescher A et al. Extra- and intracellular accumulation of ultrasmall superparamagnetic iron oxides (USPIO) in experimentally induced abscesses of the peripheral soft tissues and theit effects on magnetic resonance imaging. Magn Reson Imaging (1999) 17 (4):557-567.
5. Carlos RC, Kim HM, Hussain HK et al. Developing a prediction rule to assess hepatic malignancy in patients with cirrhosis. AJR (2002) 180:893-900.
6. Ito K, Fujita T, Shimizu A et al. Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis. AJR (2004) 183:699-705.
7. Shimizu A, Ito K, Koike S et al. Cirrhosis or chronic hepatitis: Evaluation of small (<2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology (2003) 226:550-555.
8. Mori K, Scheidler J, Helmberger T et al. Detection of malignant hepatic lesions before orthotopic liver transplantation: accuracy of ferumoxides-enhanced MR imaging. AJR (2002) 179(4):1045-51.
9. Simon G, Link TM, Wörtler K et al. Detection of hepatocellular carcinoma: comparison of Gd-DTPA and ferumoxides-enhanced MR imaging. Eur Radiol (2005) 15:895-903.
10. Ward J, Robinson PJ, Guthrie JA et al. Liver metastases in candidates for hepatic resection: Comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology (2005) 26: [Epub ahead of print].
11. Bhartia B, Ward J, Guthrie JA et al. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR (2003) 180(3):577-84.
12. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol (2002) 13:1266-1276.
13. Stroszczynski C, Gaffke G, Gnauck M et al. Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA. Radiologe (2004) 44:1185-1191.
14. Vogl TJ, Schwarz W, Blume S et al. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol (2003) 13:262-272.
15. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. EurRadiol (2004) 14:5-13.
16. Del Frate C, Bazzocchi M, Mortele KJ et al. Detection of liver metastases: comparison of gadobenetate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology (2002) 225 (3):766-772.
17. Bartolozzi C, Donati F, Cioni D et al. Detection of colorectal liver metastases: a propective multicenter trial comparino unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol (2004) 14:14-20.
18. Helmberger TK, Laubenberger J, Rummeny E et al. MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool. Eur Radiol (2002) 12(1):62-70.